In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price target of $3.00. The company’s shares closed yesterday at $0.57.
Fein covers the Healthcare sector, focusing on stocks such as Catalyst Pharma, Prothena, and Wave Life Sciences. According to TipRanks, Fein has an average return of -2.8% and a 39.40% success rate on recommended stocks.
Matinas BioPharma has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
See the top stocks recommended by analysts >>
Based on Matinas BioPharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.06 million and a GAAP net loss of $5.46 million. In comparison, last year the company had a GAAP net loss of $6.84 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company’s proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.
Read More on MTNB:
- Matinas BioPharma Provides Business Update and 2023 Strategic Outlook
- Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023
- Matinas BioPharma announces collaboration with National Resilience
- Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids
